Skip Nav Destination

Issue Archive

Select Decade

Select Year

Issue

Volume 140, Issue 17

October 27 2022

In this Issue

Blood Commentaries
Blood Spotlight
Clinical Trials and Observations
Immunobiology and Immunotherapy
Lymphoid Neoplasia
Blood Work

Blood Commentaries

KMT2A-rearranged leukemia: the shapeshifter

Ilaria Iacobucci,Charles G. Mullighan

View Articletitled, KMT2A-rearranged leukemia: the shapeshifter

Claiming the mantle of the brain

Jia Ruan

View Articletitled, Claiming the mantle of the brain

Blood Spotlight

Hemolysis, free hemoglobin toxicity, and scavenger protein therapeutics

Florence Vallelian,Paul W. Buehler,Dominik J. Schaer

View Articletitled, Hemolysis, free hemoglobin toxicity, and scavenger protein therapeutics

Clinical Trials and Observations

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3^mut+ AML ineligible for intensive chemotherapy
Clinical Trials & Observations

Eunice S. Wang,Pau Montesinos,Mark D. Minden,Je-Hwan Lee,Michael Heuser,Tomoki Naoe,Wen-Chien Chou,Kamel Laribi,Jordi Esteve,Jessica K. Altman,Violaine Havelange,Anne-Marie Watson,Carlo Gambacorti-Passerini,Elzbieta Patkowska,Shufang Liu,Ruishan Wu,Nisha Philipose,Jason E. Hill,Stanley C. Gill,Elizabeth Shima Rich,Ramon V. Tiu

View Articletitled, Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy

Supplemental data

Immunobiology and Immunotherapy

Human complete NFAT1 deficiency causes a triad of joint contractures, osteochondromas, and B-cell malignancy

Mehul Sharma,Maggie P. Fu,Henry Y. Lu,Ashish A. Sharma,Bhavi P. Modi,Christina Michalski,Susan Lin,Joshua Dalmann,Areesha Salman,Kate L. Del Bel,Meriam Waqas,Jefferson Terry,Audi Setiadi,Pascal M. Lavoie,Wyeth W. Wasserman,Jill Mwenifumbo,Michael S. Kobor,Anna F. Lee,Florian Kuchenbauer,Anna Lehman,Sylvia Cheng,Anthony Cooper,Millan S. Patel,Stuart E. Turvey,on behalf of the CAUSES Study ,

View Articletitled, Human complete NFAT1 deficiency causes a triad of joint contractures, osteochondromas, and B-cell malignancy

Supplemental data

Lymphoid Neoplasia

Epigenetic regulator genes direct lineage switching in MLL/AF4 leukemia

Ricky Tirtakusuma,Katarzyna Szoltysek,Paul Milne,Vasily V. Grinev,Anetta Ptasinska,Paulynn S. Chin,Claus Meyer,Sirintra Nakjang,Jayne Y. Hehir-Kwa,Daniel Williamson,Pierre Cauchy,Peter Keane,Salam A. Assi,Minoo Ashtiani,Sophie G. Kellaway,Maria R. Imperato,Fotini Vogiatzi,Elizabeth K. Schweighart,Shan Lin,Mark Wunderlich,Janine Stutterheim,Alexander Komkov,Elena Zerkalenkova,Paul Evans,Hesta McNeill,Alex Elder,Natalia Martinez-Soria,Sarah E. Fordham,Yuzhe Shi,Lisa J. Russell,Deepali Pal,Alex Smith,Zoya Kingsbury,Jennifer Becq,Cornelia Eckert,Oskar A. Haas,Peter Carey,Simon Bailey,Roderick Skinner,Natalia Miakova,Matthew Collin,Venetia Bigley,Muzlifah Haniffa,Rolf Marschalek,Christine J. Harrison,Catherine A. Cargo,Denis Schewe,Yulia Olshanskaya,Michael J. Thirman,Peter N. Cockerill,James C. Mulloy,Helen J. Blair,Josef Vormoor,James M. Allan,Constanze Bonifer,Olaf Heidenreich,Simon Bomken

View Articletitled, Epigenetic regulator genes direct lineage switching in MLL/AF4 leukemia

Supplemental data

KMT2A-rearranged leukemia: the shapeshifter

Ilaria Iacobucci,Charles G. Mullighan

View Articletitled, KMT2A-rearranged leukemia: the shapeshifter

Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia

Saara Laukkanen,Alexandra Veloso,Chuan Yan,Laura Oksa,Eric J. Alpert,Daniel Do,Noora Hyvärinen,Karin McCarthy,Abhinav Adhikari,Qiqi Yang,Sowmya Iyer,Sara P. Garcia,Annukka Pello,Tanja Ruokoranta,Sanni Moisio,Sadiksha Adhikari,Jeffrey A. Yoder,Kayleigh Gallagher,Lauren Whelton,James R. Allen,Alex H. Jin,Siebe Loontiens,Merja Heinäniemi,Michelle Kelliher,Caroline A. Heckman,Olli Lohi,David M. Langenau

View Articletitled, Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia

Supplemental data

Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse
Clinical Trials & Observations

Chiara Rusconi,Chan Y. Cheah,Toby A. Eyre,David Tucker,Pavel Klener,Eva Giné,Lara Crucitti,Cristina Muzi,Sara Iadecola,Gabriele Infante,Sophie Bernard,Rebecca L. Auer,Chiara Pagani,Monika Duglosz-Danecka,Heidi Mocikova,Tom van Meerten,Emanuele Cencini,Ana Marin-Niebla,Michael E. Williams,Piera Angelillo,Paolo Nicoli,Annalisa Arcari,Lucia Morello,Donato Mannina,Orsola Vitagliano,Roberto Sartori,Annalisa Chiappella,Roberta Sciarra,Piero M. Stefani,Martin Dreyling,John F. Seymour,Carlo Visco,on behalf of Fondazione Italiana Linfomi and European Mantle Cell Lymphoma Network

View Articletitled, Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse

Supplemental data

Claiming the mantle of the brain

Jia Ruan

View Articletitled, Claiming the mantle of the brain

Blood Work

κ light chain–expressing hematogones in a patient with λ-restricted CLL and multiple myeloma on daratumumab therapy

Ahmad Al-Attar,Bruce A. Woda

View Articletitled, κ light chain–expressing hematogones in a patient with λ-restricted CLL and multiple myeloma on daratumumab therapy

Cover Image

Cover Image

Bone marrow aspirate smear, stained with May Grunwald Giemsa stain, from a 4-year-old boy with relapsed acute myeloid leukemia with t(4;11)(q21;q23); KMT2A/AFF1, who presented as an infant with acute lymphoblastic leukemia with the same karyotype. See the article by Tirtakusuma et al on page 1875.
Front Matter
Table of Contents
Back Matter
Editorial Board

All Issues

Email alerts

First Edition Alert

Latest Issue Alert

Latest
Most Read
Most Cited

Data mining for second malignancies after CAR-T

Silva A, Almeida ARM, Cachucho A, et al. Overexpression of wild-type IL-7Rα promotes T-cell acute lymphoblastic leukemia/lymphoma. Blood. 2021;138(12):1040-1052.

MRD and EFS in pediatric T-lymphoblastic lymphoma

Outcomes of younger patients with mantle-cell lymphoma experiencing late relapse (>24 months): the LATE-POD study

Mutational profile of previously treated chronic lymphocytic leukemia patients progressing on acalabrutinib or ibrutinib

Table of Contents

Blood Commentaries

KMT2A-rearranged leukemia: the shapeshifter

Claiming the mantle of the brain

Blood Spotlight

Hemolysis, free hemoglobin toxicity, and scavenger protein therapeutics

Clinical Trials and Observations

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3^mut+ AML ineligible for intensive chemotherapy
Clinical Trials & Observations

Immunobiology and Immunotherapy

Human complete NFAT1 deficiency causes a triad of joint contractures, osteochondromas, and B-cell malignancy

Lymphoid Neoplasia

Epigenetic regulator genes direct lineage switching in MLL/AF4 leukemia

KMT2A-rearranged leukemia: the shapeshifter

Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia

Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse
Clinical Trials & Observations

Claiming the mantle of the brain

Blood Work

κ light chain–expressing hematogones in a patient with λ-restricted CLL and multiple myeloma on daratumumab therapy

Email alerts

ASH Publications

American Society of Hematology

Issue Archive

Table of Contents

Blood Commentaries

Blood Spotlight

Clinical Trials and Observations

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy Clinical Trials & Observations

Immunobiology and Immunotherapy

Lymphoid Neoplasia

Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse Clinical Trials & Observations

Blood Work

Cover Image

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3^mut+ AML ineligible for intensive chemotherapy
Clinical Trials & Observations

Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse
Clinical Trials & Observations